HOME >> MEDICINE >> NEWS
Aspirin withdrawal may pose risk to coronary patients

(Orlando, Florida, October 29, 2003) -- Patients with coronary artery disease who stop taking aspirin may be at risk for developing withdrawal-related coronary events, says a new study presented at CHEST 2003, the 69th annual international scientific assembly of the American College of Chest Physicians (ACCP). The study found that previously stable coronary patients experienced coronary events, including unstable angina and myocardial infarction (heart attack), within one week of aspirin withdrawal.

"The benefits of aspirin therapy in coronary patients are well known. However, the effects that aspirin withdrawal has on this group of patients are just now being studied," said lead author Emile Ferrari, MD, Professor of Cardiology, University Hospital Pasteur, Nice, France. "Our study shows that aspirin therapy can not be safely stopped in any case, but especially in patients with a history of coronary disease."

Researchers from University Hospital Pasteur reviewed the cases of 1,236 patients hospitalized for coronary syndromes to determine which patients were hospitalized due to treatment withdrawal. Of those hospitalized, 51patients experienced acute coronary events, including unstable angina, stent thrombosis, and heart attacks, less than one week after aspirin withdrawal. Prior to hospitalization, patients had been taking aspirin for at least three months. Although patients had a history of heart attacks and stable angina, none had an unstable coronary event prior to aspirin withdrawal. Reasons for aspirin withdrawal included minor surgery, dental treatment, and non-compliance. Aspirin therapy is standard in patients with coronary artery disease because of its ability to thin the blood and reduce the risk of developing acute blockage in the coronary arteries.

"Coronary patients preparing for dental work or surgery are often advised to stop taking aspirin in order to avoid increased bleeding," said Dr. Ferrari. "Our study serves as
'"/>

Contact: Arielle Green
agreen@chestnet.org
847-498-8387
American College of Chest Physicians
29-Oct-2003


Page: 1 2

Related medicine news :

1. Aspirins potential ability to prevent colon polyps may not apply equally to all
2. Aspirin underused to reduce heart disease risk in diabetic women and young adults
3. Long Island Breast Cancer Study data: Aspirin helps protect some women against breast cancer
4. Aspirin use associated with reduced risk of breast cancer
5. Aspirin use may be associated with increased risk of pancreatic cancer
6. Aspirin is most cost effective way to prevent heart disease
7. Aspirin does not reduce effectiveness of ACE inhibitors
8. Aspirin may help prevent pancreatic cancer
9. Aspirins target, the COX-2 enzyme, linked to cancer of the uterus
10. Aspirin within two days of ischemic stroke reduces deaths
11. Aspirin steps up as anti-inflammatory for arteries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aspirin withdrawal may pose risk coronary patients

(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... have a clot in their legs and are ... medication or undergo a minimally-invasive catheter-based clot removal ... difference in death rates between the two treatments, ... catheter procedure, according to a study by Temple ... a review of more than 90,000 cases nationwide., ...
(Date:7/21/2014)... The "viral reservoir" in which HIV can lie dormant ... earlier than previously thought, new animal research indicates. ... eradicate the AIDS-causing virus, said Harvard researchers working with ... presence of the viral reservoir remains the most significant ... HIV, known as HIV-1. "We found that the ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Western ... “Great College to Work For” by the Chronicle ... and also made the Honor Roll for the ... categories: Collaborative Governance, Compensation and Benefits, Confidence in ... Respect & Appreciation. , “Western University of Health ...
(Date:7/21/2014)... A new study suggests that potential help in lowering ... refrigerator. The study found that regular intake of ... supplements, may help ease the condition. Researchers looked ... probiotics and blood pressure. The studies involved a total ... pressure. People who consumed probiotics had an average ...
Breaking Medicine News(10 mins):Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
Cached News: